Altria Group Inc (MO) Stock News

AiMOGA Robotics, backed by Chery, will launch Mobo, a consumer-grade humanoid robot designed for family companionship, on October 21, 2026 in Wuhu, China. The robot features voice interaction, visual recognition, and long-term memory capabilities. AiMOGA leverages Chery's automotive R&D expertise and supply chain capabilities to bring robotics into everyday home environments, expanding beyond commercial applications.

AiMOGA Robotics, leveraging Chery's automotive expertise, is launching Mobo, a consumer-grade humanoid robot designed as a family companion. The robot features voice interaction, visual object recognition, schedule reminders, and long-term memory capabilities. Global pre-orders open on October 21, 2026, marking AiMOGA's expansion from commercial applications to residential home environments.

AiMOGA Robotics will launch Mobo, its first humanoid family companion robot designed for general consumers, on October 21, 2026, in Wuhu, Anhui. The robot features voice interaction, visual object recognition, scheduling reminders, and long-term memory to support family communication and daily routines. AiMOGA leverages Chery's automotive expertise and global R&D infrastructure to develop the robot, marking the company's expansion from commercial applications into household robotics.

Value Line, Inc. (NASDAQ: VALU) announced a quarterly cash dividend of $0.35 per common share, payable on November 10, 2026, to stockholders of record on October 26, 2026. The company has 9,382,098 shares of common stock outstanding as of October 16, 2026.

David Solomon, CEO of Goldman Sachs, has been named the new chair of The Business Council, succeeding Brian Cornell of Target Corporation. Solomon will lead the organization during a pivotal period marked by AI advancement and complex global economic challenges. The Business Council, established in 1933, serves as a forum for world-leading CEOs to collaborate on business solutions.

Tango Therapeutics announced it will present updated Phase 1/2 study data on vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP-deleted RAS-mutant metastatic pancreatic and lung cancers at the ESMO Congress 2026 in Madrid. The company will also host a PDAC-focused investor webcast on October 23, 2026.

Mowi ASA reports that primary insider Øyvind Oaland's 6,002 shares (valued at NOK 204.40 each) were sold due to an error in closing his securities trading account. The company also notes that Board members have purchased shares as partial remuneration. Mowi shares will trade ex-dividend of NOK 2.30 from August 28, 2026.

Silicon Motion (SIMO) declined 9.35% in trading, underperforming the S&P 500's 1.11% loss. The chip company is expected to report earnings on October 28, 2026, with projected EPS of $3.3 (230% YoY growth) and revenue of $532.81 million (120% YoY growth). SIMO holds a Zacks Rank #3 (Hold) with a Forward P/E of 22.11, trading at a PEG ratio of 0.41, which is significantly lower than its industry average of 1.37.

Altria Group (MO) has been heavily searched on Zacks.com lately. The stock returned +2.5% over the past month, outperforming the S&P 500's +2.1% gain. Altria holds a Zacks Rank #2 (Buy) rating with stable earnings estimates showing +4.6% growth for the current fiscal year and +3.1% for the next year. Revenue growth is modest at +2.1% for the current year. The company trades at par with peers with a C valuation grade, suggesting it may outperform the broader market in the near term.

Modine Manufacturing (MOD), a heating and cooling products maker, has been trending on Zacks.com. Despite a -3.5% return over the past month versus the S&P 500's +2.1% gain, the company shows strong fundamentals with expected earnings growth of +38.7% for the current quarter and +53% for the fiscal year. The stock has a Zacks Rank #2 (Buy) rating, trades at a discount to peers (Value Style Score B), and has consistently beaten earnings estimates. Revenue is projected to grow +27% and +21.4% for the current and next fiscal years respectively.

Silicon Motion (SIMO), a chip company, has gained 3.1% over the past month and is trending among investors. The company shows strong earnings growth expectations (+214.4% for current fiscal year) and revenue growth (+112.9%), with a history of beating consensus estimates. However, it carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (Grade D), suggesting it may perform in line with the broader market in the near term.

Treasure Global Inc. (NASDAQ: TGL) announced a strategic Memorandum of Understanding with Union Concept Trading Pte. Ltd. to establish medical supply and pharmaceutical distribution across Malaysia and regional markets. The collaboration leverages Treasure Global's digital commerce capabilities with Union Concept's healthcare expertise. Southeast Asia's medical device market is projected to reach $15.8 billion by 2028, with Malaysia's pharmaceutical market expected to grow to RM15.5 billion by 2027. The MOU includes a six-month exclusivity period, with definitive agreements still subject to negotiation.

Marwynn Holdings announced a memorandum of understanding with OmniX Technologies to provide AI computing infrastructure and related services through its subsidiary NexaCore. Under the 18-month phased evaluation period, NexaCore will serve as OmniX's preferred provider for AI computing capacity, with potential collaboration spanning AI infrastructure, applications, and real-world asset securities infrastructure.

Investment firms of ultra-wealthy families aren't immune to FOMO.

Silicon Motion (SIMO) declined 8.36% in recent trading, underperforming the S&P 500's 0.47% loss. Despite a monthly gain of 2.91%, the stock lags its sector. Analysts expect strong earnings growth of 230% YoY and revenue growth of 120.17%, with full-year projections showing 214.37% earnings growth. The stock holds a Zacks Rank #3 (Hold) with a Forward P/E of 25.62, trading at a premium to its industry average.

Regeneron announced presentations of new clinical research at ESMO Congress 2026, highlighting late-breaking Phase 3 data for Libtayo (cemiplimab) in cutaneous squamous cell carcinoma, Phase 2 neoadjuvant treatment data, and new research on Factor XI antibodies for cancer-associated thrombosis. The company is presenting 10 abstracts covering trials in CSCC, NSCLC, ovarian cancer, melanoma, and cancer-associated thrombosis.

The global cell and gene therapy biomanufacturing market is projected to grow from $5.0 billion in 2026 to $8.7 billion by 2031, driven by an 11.7% CAGR. Growth is fueled by increasing regulatory approvals, rising demand for scalable manufacturing infrastructure, and investments in automation and modular systems. However, high production costs, regulatory complexity, and workforce shortages remain significant challenges.

A class action lawsuit has been filed against Replimune Group Inc. for allegedly making materially false statements regarding its Biologics License Application (BLA). The lawsuit claims the company failed to disclose that FDA study design concerns were not addressed and that submitted data from an early analysis included only 40 of 400 planned patients, likely causing FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 can apply to be lead plaintiff by October 5, 2026.

A class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales.

A class action lawsuit has been filed against Blaize Holdings, Inc. (NASDAQ: BZAI) for allegedly making false and misleading statements regarding revenue recognition and announcing transactions with unequipped entities to create an appearance of growth. Investors who purchased Blaize securities between July 17, 2025 and August 13, 2026 have until October 5, 2026 to apply as lead plaintiff.

Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Hims & Hers Health, Inc. following FTC allegations that the telehealth provider shared consumers' sensitive health information with third-party advertising platforms including Meta and Snap, and engaged in deceptive billing practices. The lawsuit covers securities purchased between August 4, 2025 and July 29, 2026, with a lead plaintiff deadline of November 2, 2026. Hims & Hers shares declined nearly 15% following the FTC announcement.

Silicon Motion (SIMO) outperformed the broader market on September 30, 2026, closing up 1.39% while the S&P 500 declined 0.25%. The stock has gained 16.35% over the past month and is forecasted to report strong earnings with EPS expected at $3.3 (up 230% YoY) and revenue of $532.81 million (up 120% YoY). SIMO holds a Zacks Rank #1 (Strong Buy) rating with a PEG ratio of 0.46, though it trades at a Forward P/E of 24.76, above its industry average.

Altria (MO) is trending among investors but faces headwinds according to Zacks analysis. The stock has underperformed the S&P 500 over the past month (-1.2% vs -0.4%). While earnings estimates remain stable with modest growth projections (4.6% for current fiscal year, 3% for next year), Altria received a Zacks Rank #4 (Sell) rating, suggesting it may underperform the broader market in the near term. The company trades at par with peers based on valuation metrics.

Modine Manufacturing (MOD), a heating and cooling products maker, is attracting investor attention with strong earnings growth expectations. The company is projected to report 37.7% year-over-year earnings growth for the current quarter and 52.4% for the fiscal year. However, it maintains a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term. The stock trades at par with its peers based on valuation metrics.

Galaxy Gaming announced that its MONOPOLY Table Games Progressive has won Product Innovation of the Year at the Global Gaming Awards Americas 2026. The linked progressive table game, developed through an exclusive licensing agreement with Hasbro, has achieved widespread installations across North America and EMEA. Galaxy Gaming is showcasing new MONOPOLY-branded games and Galaxy Link technology at G2E 2026.

The global microporous materials market is projected to grow from $5.9 billion in 2024 to $7.2 billion by 2030, expanding at a 3.2% CAGR. Growth is driven by rising demand for carbon capture, clean fuels, purification, and advanced manufacturing applications. Key players including BASF, Honeywell UOP, Albemarle, and Evonik are accelerating development of metal-organic frameworks (MOFs) and carbon-capture technologies. Asia-Pacific, particularly China, is expected to see strong growth at 5.8% CAGR.

L'Oréal completed a successful bond issuance of €2 billion across three tranches on September 24, 2026: €850 million at 2 years with variable rate (Euribor 3M + 27 bp), €500 million at 3 years at 3.75% fixed, and €650 million at 7 years at 4.00% fixed. The bonds are expected to be rated AA (Stable) by S&P and Aa1 (Stable) by Moody's, with listing on Euronext Paris on September 30, 2026.

HUTCHMED announced that two Phase III studies evaluating the savolitinib and osimertinib combination for non-small cell lung cancer will be presented at ESMO Congress 2026 in Madrid. The SAFFRON global study and SANOVO China study both demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared to chemotherapy and osimertinib monotherapy, respectively. The all-oral, chemo-free combination has been selected for high-profile oral presentations including a Presidential Symposium.

Swarmer, Inc. announced a nonbinding memorandum of understanding with Vectus Air Defense Systems to manufacture end-to-end air defense systems in Poland. Vectus has confirmed intent to purchase at least 40 systems in year one and 80+ in year two, with each system retailing at approximately $5-6 million. The systems will feature combat-proven 20mm rotary cannons capable of firing 6,000 rounds per minute, designed to provide cost-effective air defense against drone threats.

UnitedHealth Group (UNH) and Molina Healthcare (MOH) are compared as investment options in the managed care sector. UNH benefits from diversification through its Optum platform, improving profitability, and a stronger balance sheet, but faces membership pressure. MOH offers a focused recovery story with stabilizing Medicaid economics and growth in Medicare dual-eligible plans, commanding a higher valuation. Despite UNH's operational strengths, MOH is rated as the more attractive investment due to stronger projected earnings rebound, earning a Zacks Rank #1 (Strong Buy) versus UNH's Rank #2 (Buy).